- Service name
- Autologous Bone Marrow Cell Regenerative Therapy Service
- Cell source
- Autologous bone marrow collection; no allogeneic donation.
- Preparation standards
- GMP-grade clean laboratory with comprehensive GMP quality-control testing.
- Main indications
- Liver cirrhosis, lower-limb ischemia, osteoarthritis, femoral head necrosis, refractory diabetes and blood disorders.
- Treatment model
- Minimally invasive interventional infusion without open surgery; 1–3 days of hospitalization.
- Safety assurance
- Autologous cells are used; technology credentials, clinical institution and individual safety assessment are subject to signed arrangements and professional assessment.
Specific indications, treatment plans, hospitalization and outcome assessment depend on evaluation by a qualified medical institution and the actual consultation.
Core approach: dietary intervention, meridian embedding and Chinese medicine regulation as the main components, with cell therapy as an adjunct.
Positioning: evidence-informed integration · individualized planning · in-depth stratification.
Program layers
-
01
Diet and lifestyle intervention as the foundation
A health manager provides 1-to-1 guidance throughout daily diet and lifestyle changes. This basic management applies to all patients and forms an important foundation for diabetes care.
-
02
Meridian embedding as an external-treatment component
An extension of traditional acupuncture: absorbable threads are placed at acupoints and gradually absorbed over 15–30 days, providing sustained, gentle stimulation.
- Five pathways work together to support microcirculation, the brain–gut axis, gastrointestinal motility, gut microbiota balance, and oxidative/inflammatory regulation.
- Treatment interval: threads are typically absorbed over 15–30 days; frequency should be determined after professional assessment.
-
03
Chinese medicine pattern-based care as an intensifying component
Pattern-based treatment may be used alongside glucose management to address symptoms and diabetes-related complications.
-
04
Emerging adjunct: stem-cell islet regeneration therapy
Cell therapy is presented as an emerging adjunctive direction; eligibility, feasibility and compliance requirements require professional assessment.
Treatment content must be tailored to condition, medication history and test results and does not replace standard care.
- Service name
- Cross-Border Precision Oncology Diagnosis and Treatment Service
- Core technologies
- Proton and heavy-ion therapy, yttrium-90 microspheres, NanoKnife, cryoablation, targeted therapy, immunotherapy, CAR-T cell therapy, BNCT (boron neutron capture therapy), specialized medicines and traditional Chinese medicine.
- Diagnostic model
- MDT (multidisciplinary team) consultation with an individualized oncology treatment plan.
- Service support
- Medical visa assistance, bilingual support throughout the process, medication guidance, rehabilitation follow-up and psychological support.
Who it may serve
- Patients with early-stage cancer seeking minimally invasive treatment.
- Patients with mid- to late-stage tumors seeking precision combination treatment.
- Patients whose previous treatment has not achieved the desired result and who need an alternative treatment plan.
The specific medical institution, treatment approach, eligibility, cost and expected outcomes require case-by-case professional assessment.